Emergent BioSolutions Inc. 8-K

What Happened

• Emergent BioSolutions Inc. held its 2026 Annual Meeting on April 29, 2026 and filed the vote results on Form 8-K. A total of 40,346,672 shares were present or represented by proxy, representing 78.12% of the 51,644,495 shares outstanding as of the March 6, 2026 record date.
• Four Class II director nominees were elected to terms through the 2029 annual meeting: Sujata Dayal (29,593,251 For; 1,466,690 Withhold; 9,286,731 Broker non‑votes), John Fowler, Jr. (30,647,734 For; 412,207 Withhold; 9,286,731 Broker non‑votes), Zsolt Harsanyi, Ph.D. (28,672,319 For; 2,387,622 Withhold; 9,286,731 Broker non‑votes), and Joseph Papa (29,271,291 For; 1,788,650 Withhold; 9,286,731 Broker non‑votes).
• Other outcomes: Ernst & Young LLP was ratified as the company’s independent registered public accounting firm for FY2026 (38,947,477 For; 1,271,938 Against; 127,257 Abstain). The advisory vote on 2025 executive compensation was approved (18,187,878 For; 11,988,552 Against; 883,511 Abstain; 9,286,731 Broker non‑votes). The amendment to increase shares available under the Amended and Restated Stock Incentive Plan was approved (16,972,952 For; 14,023,162 Against; 63,827 Abstain; 9,286,731 Broker non‑votes). The amended Plan was filed as Exhibit 10.1 to the Form 8‑K.

Key Details

• Meeting date: April 29, 2026; record date: March 6, 2026.
• Shareholder turnout: 40,346,672 shares voted (78.12% of outstanding).
• Auditor ratification: Ernst & Young LLP approved — 38,947,477 For.
• Stock Incentive Plan amendment approved — For: 16,972,952; Against: 14,023,162; Exhibit 10.1 filed.

Why It Matters

• Board continuity confirmed: all nominated Class II directors were elected, which maintains the current board composition through the 2029 annual meeting.
• Auditor ratification keeps Ernst & Young as the company’s independent auditor for FY2026, a routine but important governance item.
• Approval of the stock incentive plan amendment permits more equity awards going forward; this can enable future employee and executive compensation grants and may have dilutive implications for shareholders. The advisory "say on pay" passed, but the vote margins indicate a meaningful number of dissenting votes, which investors may monitor as governance or compensation feedback.